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Introduction Ventricular myocardial remodeling is a cause of heart failure
in ARVD patients. Angiotensin-converting enzyme (ACE) inhibitors inhibit
the TGF-B pathway and have an anti-apoptotic action. ACE inhibitors are cur-
rently prescribed to reduce hypertension, to treat heart failure or to protect the
heart following ischemic insult. Expression patterns of matrix metallopro-
teinase-9 (MMP-9) and its specific inhibitors, tissue inhibitor of metallopro-
teinases (TIMP) 1 and 2, are closely correlated with physiological and
pathological processes characterized by the degradation and accumulation of
the extracellular matrix. We aimed to study the turnover of tissue collagen in
patients.
Methods Dosages ofmmP9 and its inhibitors, TIMP1 and TIMP2, were
performed in 26 patients treated with beta blockers (BB) and ACEs and in 20
patients treated with BB without ACEs. Each patient had blood samples taken
one year apart. Tissue collagen turnover was identified by the evolution of
themmP9/TIMP1 ratio and themmP9/TIMP2 ratio between the 2 time samples
(Student’s t-test for paired samples).
Results A stabilization of themmP9/TIMP1 andmmP9/TIMP2 ratio was
present in patients treated with angiotensin-converting enzyme inhibitors
(3.04±1.88 vs 3.36±2.86 formmP9/TIMP1; 8.79±8.18 vs 8.31±6.70 formmP9/
TIMP2). In contrast, there was a significant increase of themmP9/TIMP1 ratio
in patients treated without ACE inhibitors (2.74±2.36 vs 4.53±3.62, p=0.03).
No significant increase ofmmP9/TIMP2 was observed (7.39±5.17 vs
9.00±6.64) in these patients. The increasedmmP9/TIMP1 ratio for BB patients
was triggered by an increase inmmP9 concentration (554.8±368.5 vs.
876.0±619.7, p=0.04) and a decrease in TIMP1 concentration (223.2±72.8 vs
205.1±71.6, p=0.01).
Conclusion This study suggests that ACE inhibitors decrease myocardial
damage in ARVD patients and strengthens the need for a prospective clinical
evaluation of antifibrotic drugs in this disease.
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Introduction Mutations in the DSC2 gene cause Arrhythmogenic Right
Ventricular Dysplasia (ARVD). The mechanisms by which these mutations
confer histologic substrate remain unknown. It has been suggested that endog-
enous caspase-1 activity promotes the magnitude of the inflammatory
response. 
Materials and Methods Fragments of cardiac tissue from 2 patients were
collected after macroscopic and histopathological examination the patients’
hearts. A 63-year-old patient with ARVD caused by a DSC2 mutation
(p.Arg132Cys) underwent heart transplantation. The diseased heart genome-
wide expression profiling was compared with that of a non-diseased donor
heart. The retained genes of interest were listed and classified according to
their biological functions using Ingenuity Pathways Analysis (Ingenuity Sys-
tems Inc., Mountain View, CA). RT-qPCR and Western Blot (WB) were used
to confirmed genes of interest.
Results Transcriptomic and RT-PCR data first revealed a down-expression
of DSC2 mRNA and an unexpected overexpression of DSC3 mRNA in the
posterior right ventricle of the ARVC patient (Figure) In the ARVD heart,
DSC3 was found to be cleaved. Prediction software revealed that this cleavage
could be due to Caspase-1. We observed an overexpression of Casp1 and
other elements of inflammasome (CARD16, NLRP3) in the posterior RV of
the ARVC patient. A down-expression of DSG2, DSP and RyR2 was also
documented. Biological pathways analysis identified a relationship of Casp1
with apoptosis (BCL2, FOS), fibrogenesis (Col3A1, Col4A1, Col4A2,mmP9)
and adipogenesis (IGF1, ADIPOQ) in the ARVC heart.
Conclusion These findings suggest that in ARVD patients with a DSC2
variant: 1) there is a switch DSC2/DSC3 2) endogenous caspase-1 activity, by
cleaving DSC3, contributes to desmosome dysfunction.
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Background Inflammation is deeply involved in the pathophysiology of
ischemia-reperfusion (I/R) lesions and remodeling phenomena after an acute
myocardial infarction (AMI), responsible for heart failure. Colchicine exerts
anti-inflammatory effects, through the inhibition of neutrophil chemoattrac-
tion, the inflammasome and proinflammatory cytokines. We aimed at eva-
luating the impact of colchicine on the infarct size in a mouse model.
Method Myocardial I/R injury were induced in 19, 8 to 10 weeks, male
C57BL/6 mice, after left thoracotomy, by ligating the left coronary artery for
45min followed by reperfusion. 400 μg/kg of Colchicine or placebo was
administrated via the intraperitoneal (i.p) route 25 minutes before the reperfu-
sion (blinded administration). 24 hours later, mice were sacrificed after intra-
cardiac Evans blue injection, the heart was removed and the left ventricle
(LV) was cut in transverse slices stained with Triphenyl-tetrazolium chloride
(TTC). The area at risk (AAR) and infarcted area (IA) were determined by
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Abstract 0193 – Figure: RT-PCR of DSC3 in heart samples
